Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we confirm that PTEN mutations in sporadic thyroid cancer are infrequent as we found one point mutation and one heterozygous deletion of PTEN gene in 26 tumors and eight cell lines screened.
|
10918569 |
2000 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Strong correlations (0.68 ≤ r ≤ 1.0) were observed between PIK3C3 and PIM3 in breast cancer, between PIK3C3 and PTEN in breast and ovary cancers, and between PIM3 and PTEN in breast, kidney, liver, and thyroid cancers during disease progression, implicating that the correlations for cancer network gene expressions could serve as a supplement to current clinical biomarkers, such as cancer antigens, for early cancer diagnosis.
|
24818135 |
2014 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We show here that adenosine triphosphate (ATP) regulates PTEN subcellular localization in a variety of different cancer cell lines, including those derived from breast, colon and thyroid carcinomas.
|
18579579 |
2008 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline PTEN mutations cause 85% of Cowden syndrome (CS), characterized by a high risk of breast and thyroid cancers, and 65% of Bannayan-Riley-Ruvalcaba syndrome (BRRS), characterized by lipomatosis, hemangiomas and speckled penis.
|
17405772 |
2007 |
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
1alpha,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness.
|
15890670 |
2005 |
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our data define a novel mechanism of PI3K/AKT hyperactivation and outline a regulatory role for miR-146b in suppressing PTEN expression, a frequent observation in thyroid cancer.
|
29353884 |
2018 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Sequencing of tumor tissue revealed a second hit in PTEN in the thyroid carcinoma and VC, confirmed by a PTEN loss and activation of the PI3K/AKT pathway in immunohistochemistry.
|
30111295 |
2018 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
At the present time, no study has been undertaken to consider thyroid cancer treatment via FOXOs and PTEN targeting.
|
26597586 |
2016 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overall, our results suggest that PTEN can function as an important modulator of extracellular matrix proteins in thyroid cancer.
|
15707585 |
2005 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTEN knockdown in thyroid cancer cell lines stabilized intracellular NIS protein by promoting an interaction with NIS-LARG (leukemia-associated RhoA guanine exchange factor).
|
30217930 |
2018 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Notably, individuals with SDH(var+) alone had the highest thyroid cancer prevalence (24/47) compared with PTEN(mut+) patients (27/105, P = 0.002) or PTEN(mut+)/SDH(var+) carriers (6/22, P = 0.038).
|
21979946 |
2012 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The latter could explain the clinically observed decrease in thyroid cancer prevalence in patients with co-existent PTEN mutations and SDHx variants.
|
28164237 |
2017 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors.
|
12203792 |
2002 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.
|
9140396 |
1997 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
HMGB1-Induced Cross Talk between PTEN and miRs 221/222 in Thyroid Cancer.
|
26106610 |
2015 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline phosphatase and tensin homolog (PTEN) mutations cause Cowden syndrome (CS), associated with breast and thyroid cancers.
|
20600018 |
2010 |
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our study shows that low blood PTEN protein expression could serve as a screening molecular correlate to predict for germline PTEN mutation in CS and CS-like presentations of thyroid cancer.
|
23066114 |
2012 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A total of 32 of 225 PTEN mutation+ patients (14%) had thyroid cancer: 52% papillary, 28% follicular-variant papillary, 14% follicular, and 6% anaplastic.
|
23158187 |
2012 |
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We show that SRC inhibition could rescue SDHD dysfunction-induced cellular phenotype and tumorigenesis only when wild-type PTEN is expressed, in thyroid cancer lines.
|
25149476 |
2015 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutations in BRAF, NRAS, KRAS and PTEN, that are known to be involved in thyroid cancer biology, were detected in seven FNA samples.
|
24834793 |
2015 |
Thyroid carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
PTEN promoter methylation in sporadic thyroid carcinomas.
|
16487009 |
2006 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the PTEN gene, which cause Cowden syndrome, are known to be one of the genetic factors for primary thyroid and breast cancers; however, PTEN mutations are found in only a small subset of research participants with non-syndrome breast and thyroid cancers.
|
26699384 |
2016 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results suggest that downregulation of PTEN expression at the mRNA level plays a role in PTEN inactivation in thyroid cancer and PTEN exerts its tumour-suppressive effect on thyroid cancer through the inhibition of cell cycle progression alone or both cell cycle progression and cell death.
|
11159944 |
2001 |
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Whereas PTEN inactivation is uncommon in sporadic thyroid cancer, activation of growth factor pathways that signal through Akt is frequently identified.
|
11507060 |
2001 |
Thyroid carcinoma
|
0.500 |
GenomicAlterations
|
disease |
CGI |
|
|
|